A Randomized, Open-label, Single Dose, Two-way Replicate Crossover Phase 1 Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1019" and Co-administration of "BR1019-3" and "BR1019-2" in Healthy Volunteers
Latest Information Update: 11 Nov 2024
Price :
$35 *
At a glance
- Drugs BR 1019 (Primary) ; BR1019-2 (Primary)
- Indications Essential hypertension; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Boryung Pharmaceutical
- 08 Nov 2024 Status changed from not yet recruiting to active, no longer recruiting.
- 22 Oct 2024 New trial record